PRKAA1 and prostate carcinoma: Similarly, inhibition of complex I (metformin) or glycolysis (2-deoxyglucose) alone resulted in only moderate activation of AMPK, whereas inhibition of both metabolic pathways resulted in greater activation of AMPK in prostate cancer cells and enhanced apoptosis when metformin and 2-deoxyglucose were combined as an anticancer treatment [52,53].